

Europäisch s Patentamt  
European Patent Office  
Office européen des brevets



(11) **EP 0 745 375 A1**

(12) **EUROPEAN PATENT APPLICATION**

(43) Date of publication:  
04.12.1996 Bulletin 1996/49

(51) Int Cl.<sup>6</sup>: **A61K 7/48**

(21) Application number: **96303183.6**

*see US - 5,536,740*

(22) Date of filing: **08.05.1996**

(84) Designated Contracting States:  
**CH DE ES FI FR GB IT LI NL SE**

(30) Priority: **01.06.1995 US 457900**

(71) Applicants:  
• **UNILEVER PLC**  
London EC4P 4BQ (GB)  
Designated Contracting States:  
**GB**  
• **UNILEVER N.V.**  
3013 AL Rotterdam (NL)  
Designated Contracting States:  
**CH DE ES FI FR IT LI NL SE**

(72) Inventors:  
• **Granger, Steward Paton**  
Paramas, New Jersey 07652 (US)  
• **Rawlings, Anthony Vincent**  
Stockport, SK3 0XN (GB)  
• **Scott, Ian Richard**  
Allendale, New Jersey 07401 (US)

(74) Representative: **Evans, Jacqueline Gail Victoria**  
Unilever plc  
Patent Division  
Colworth House  
Sharnbrook  
Bedford MK44 1LQ (GB)

(54) **Skin care compositions containing dimethyl imidazolidinone and retinol or retinyl ester**

(57) Dimethyl imidazolidinone in combination with either retinol or retinyl ester resulted in a synergistic enhancement in keratinocyte proliferation and synergistic

inhibition of keratinocyte differentiation. The effects of the retinol or retinyl esters in combination with dimethyl imidazolidinone were analogous to treatment with retinoic acid.

**EP 0 745 375 A1**

**Description****FIELD OF THE INVENTION****BACKGROUND OF THE INVENTION**

Retinol (vitamin A) is an endogenous compound which occurs naturally in the human body and is essential for normal epithelial cell differentiation. Natural and synthetic vitamin A derivatives have extensively been used in the treatment of a variety of skin disorders and have been used as skin repair or renewal agents. Retinoic acid has been employed to treat a variety of skin conditions, e.g., acne, wrinkles, psoriasis, age spots and discoloration. See e.g., Vahlquist, A. et al., *J. Invest. Dermatol.*, Vol. 94, Holland D.B. and Cunliffe, W.J. (1990), pp. 496-498; Ellis, C.N. et al., "Pharmacology of Retinols in Skin", *Vasel*, Karger, Vol. 3, (1989), pp. 249-252; Lowe, N.J. et al., "Pharmacology of Retinols in Skin", Vol. 3, (1989), pp. 240-248; PCT Patent Application No. WO 93/19743. Retinol and retinyl esters, such as retinyl acetate and retinyl palmitate, are easier to formulate/stabilize than retinoic acid. Unfortunately, retinol and retinyl esters are less effective than retinoic acid at providing skin benefits. The present invention is based, in part, on the discovery that certain combinations of retinol or retinyl esters with dimethyl imidazolidinone result in a synergistic improvement in keratinocyte proliferation and differentiation. The effects of dimethyl imidazolidinone combined with retinol or a retinyl ester were analogous to the effects of retinoic acid. Thus, a mixture of fatty acid amides with retinol or retinyl esters mimics retinoic acid yet is easier to use than retinoic acid.

Dimethyl imidazolidinone is currently used in cosmetic products to combat bacterial contamination. The art does not disclose, however, skin conditioning compositions based on synergistic combinations of dimethyl imidazolidinone with retinol or a retinyl ester. None of the art cited above addresses the need for an effective alternative to retinoic acid.

**SUMMARY OF THE INVENTION**

The present invention includes, in part, a skin conditioning composition containing:

- (a) from 0.001% to 10% of retinol or a retinyl ester;
- (b) from 0.01% to 10% of dimethyl imidazolidinone; and
- (c) a cosmetically acceptable vehicle.

The term "conditioning" as used herein means prevention and treatment of dry skin, photodamaged skin, appearance of wrinkles, age spots, aged skin, increasing stratum corneum flexibility, and generally increasing the quality of skin. The composition may be used to improve skin desquamation and epidermal differentiation.

The presence of dimethyl imidazolidinone in the inventive product substantially improves the performance of retinol or a retinyl ester, i.e., dimethyl imidazolidinone substantially increases the ability of retinol or a retinyl ester to affect cellular proliferation and differentiation. Dimethyl imidazolidinone has no or little effect on improving skin benefit when used alone; a substantial increase in skin benefit is only realized when dimethyl imidazolidinone is combined with retinol or a retinyl ester. In short, the present invention is based, at least in part, on the discovery of synergistic interaction between retinol or a retinyl ester and dimethyl imidazolidinone.

By virtue of including dimethyl imidazolidinone into compositions containing retinol or a retinyl ester, the performance of the compositions is substantially improved. Alternatively, lower levels of retinol or a retinyl ester may be included in the composition containing dimethyl imidazolidinone to equal the performance of a similar formulation without dimethyl imidazolidinone.

**DESCRIPTION OF THE PREFERRED EMBODIMENT**

The inventive compositions contain, as a first essential ingredient, a compound selected from the group consisting of retinol or a retinyl ester. The term "retinol" includes the following isomers of retinol: all-trans-retinol, 13-cis-retinol, 11-cis-retinol, 9-cis-retinol, 3,4-didehydro-retinol. Preferred isomers are all-trans-retinol, 13-cis-retinol, 3,4-didehydro-retinol, 9-cis-retinol. Most preferred is all-trans-retinol, due to its ready commercial availability.


Retinyl ester is an ester of retinol. The term "retinol" has been defined above. Retinyl esters suitable for use in the present invention are C<sub>1</sub>-C<sub>30</sub> esters of retinol, preferably C<sub>2</sub>-C<sub>20</sub> esters, and most preferably C<sub>2</sub>, C<sub>3</sub>, and C<sub>16</sub> because they are more commonly available. Examples of retinyl esters include but are not limited to: retinyl palmitate, retinyl formate, retinyl acetate, retinyl propionate, retinyl butyrate, retinyl valerate, retinyl isovalerate, retinyl hexanoate, retinyl heptanoate, retinyl octanoate, retinyl nonanoate, retinyl decanoate, retinyl undecanoate, retinyl laurate, retinyl tride-

canoate, retinyl myristate, retinyl pentadecanoate, retinyl heptadecanoate, retinyl stearate, retinyl isostearate, retinyl nonadecanoate, retinyl arachidonate, retinyl behenate, retinyl linoleate, retinyl oleate.

The preferred ester for use in the present invention is selected from retinyl palmitate, retinyl acetate and retinyl propionate, because these are the most commercially available and therefore the cheapest.

Retinol or retinyl ester is suitably employed in the inventive composition in an amount of from 0.001% to 10%, preferably in an amount of from 0.01% to 1%, most preferably in an amount of from 0.01% to 0.5%.

The second essential ingredient of the inventive compositions is dimethyl imidazolidinone. It has the following formula:



Dimethyl imidazolidinone is suitably included in the inventive compositions in an amount ranging from 0.001% to 10%, preferably from 0.01% to 1%, most preferably from 0.1% to 0.5%.

The ratio of retinol or a retinyl ester to dimethyl imidazolidinone in the inventive compositions is generally in the range of from 500:1 to 1:500, preferably in the range of from 60:1 to 1:160.

#### Optional Skin Benefit Materials and Cosmetic Adjuncts

An oil or oily material may be present, together with an emulsifier to provide either a water-in-oil emulsion or an oil-in-water emulsion, depending largely on the average hydrophilic-lipophilic balance (HLB) of the emulsifier employed.

Various types of active ingredients may be present in cosmetic compositions of the present invention. Actives are defined as skin benefit agents other than emollients and other than ingredients that merely improve the physical characteristics of the composition. Although not limited to this category, general examples include sunscreens and tanning agents.

Sunscreens include those materials commonly employed to block ultraviolet light. Illustrative compounds are the derivatives of PABA, cinnamate and salicylate. For example, octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone (also known as oxybenzone) can be used. Octyl methoxycinnamate and 2-hydroxy-4-methoxy benzophenone are commercially available under the trademarks, Parsol MCX and Benzophenone-3, respectively. The exact amount of sunscreen employed in the emulsions can vary depending upon the degree of protection desired from the sun's UV radiation.

Another preferred optional ingredient is selected from essential fatty acids (EFAs), i.e., those fatty acids which are essential for the plasma membrane formation of all cells, in keratinocytes EFA deficiency makes cells hyperproliferative. Supplementation of EFA corrects this. EFAs also enhance lipid biosynthesis of epidermis and provide lipids for the barrier formation of the epidermis. The essential fatty acids are preferably chosen from linoleic acid,  $\gamma$ -linolenic acid, homo- $\gamma$ -linolenic acid, columbinic acid, eicosa-(n-6,9,13)-trienoic acid, arachidonic acid,  $\gamma$ -linolenic acid, timnodonic acid, hexanoic acid and mixtures thereof.

Emollients are often incorporated into cosmetic compositions of the present invention. Levels of such emollients may conveniently range from 0.5% to 50%, preferably between 5% and 30% by weight of the total composition. Emollients may be classified under such general chemical categories as esters, fatty acids and alcohols, polyols and hydrocarbons.

Esters may be mono- or di-esters. Acceptable examples of fatty di-esters include dibutyl adipate, diethyl sebacate, diisopropyl dimerate, and dioctyl succinate. Acceptable branched chain fatty esters include 2-ethyl-hexyl myristate, isopropyl stearate and isostearyl palmitate. Acceptable tribasic acid esters include triisopropyl trilinoleate and tri-lauryl citrate. Acceptable straight chain fatty esters include lauryl palmitate, myristyl lactate, oleyl eurate and stearyl oleate. Preferred esters include coco-caprylate/caprate (a blend of coco-caprylate and coco-caprate), propylene glycol myristyl ether acetate, diisopropyl adipate and cetyl octanoate.

Suitable fatty alcohols and acids include those compounds having from 10 to 20 carbon atoms. Especially preferred are such compounds such as cetyl, myristyl, palmitic and stearyl alcohols and acids.

Among the polyols which may serve as emollients are linear and branched chain alkyl polyhydroxyl compounds. For example, propylene glycol, sorbitol and glycerin are preferred. Also useful may be polymeric polyols such as polypropylene glycol and polyethylene glycol. Butylene and propylene glycol are also especially preferred as penetration enhancers.

Exemplary hydrocarbons which may serve as emollients are those having hydrocarbon chains anywhere from 12 to 30 carbon atoms. Specific examples include mineral oil, petroleum jelly, squalene and isoparaffins.

Another category of functional ingredients within the cosmetic compositions of the present invention are thickeners. A thickener will usually be present in amounts anywhere from 0.1% to 20% by weight, preferably from 0.5% to 10% by weight of the composition. Exemplary thickeners are cross-linked polyacrylate materials available under the trade-mark Carbopol from the B.F. Goodrich Company. Gums may be employed such as xanthan, carrageenan, gelatin, karaya, pectin and locust beans gum. Under certain circumstances the thickening function may be accomplished by a material also serving as a silicone or emollient. For instance, silicone gums in excess of 10 centistokes and esters such as glycerol stearate have dual functionality.

Powders may be incorporated into the cosmetic composition of the invention. These powders include chalk, talc, Fullers earth, kaolin, starch, smectites clays, chemically modified magnesium aluminum silicate, organically modified montmorillonite clay, hydrated aluminum silicate, fumed silica, aluminum starch octenyl succinate and mixtures thereof.

Other adjunct minor components may also be incorporated into the cosmetic compositions. These ingredients may include coloring agents, opacifiers and perfumes. Amounts of these materials may range anywhere from 0.001% up to 20% by weight of the composition.

### **Use of the Composition**

The composition according to the invention is intended primarily as a product for topical application to human skin, especially as an agent for conditioning and smoothening of the skin, and preventing or reducing the appearance of wrinkled or aged skin.

In use, a small quantity of the composition, for example from 1 to 5ml, is applied to exposed areas of the skin, from a suitable container or applicator and, if necessary, it is then spread over and/or rubbed into the skin using the hand or fingers or a suitable device.

### **Product Form and Packaging**

The topical skin and/or hair treatment composition of the invention can be formulated as a lotion having a viscosity of from 4,000 to 10,000 mPas, a fluid cream or gel having a viscosity of from 10,000 to 20,000 mPas or a cream having a viscosity of from 20,000 to 100,000 mPas or above. The composition can be packaged in a suitable container to suit its viscosity and intended use by the consumer. For example, a lotion or fluid cream can be packaged in a capsule or a bottle or a roll-ball applicator or a propellant-driven aerosol device or a container fitted with a pump suitable for finger operation. When the composition is a cream, it can simply be stored in a capsule or a non-deformable bottle or squeeze container, such as a tube or a lidded jar.

The invention accordingly also provides a closed container containing a cosmetically acceptable composition as herein defined.

The following specific examples further illustrate the invention.

## **MATERIALS AND METHODS**

### **Cell Culture:**

Human keratinocytes, isolated from neonatal foreskin by trypsin treatment were grown in Dulbecco Modification Eagle (DME) Hams F12 (1:1) medium/10% fetal calf serum in the presence of irradiated 3T3 mouse fibroblasts for establishing dividing keratinocyte colonies. Cells were grown under the above condition until their second passage and kept frozen for future use. Frozen second passage keratinocytes were thawed and plated into the above medium and grown for five days before they were switched to a serum-free MCDB 153-based medium keratinocyte growth medium (KGM) from Clonetics Corporation, San Diego, CA, containing 0.15 mM Ca, or keratinocyte serum-free media (KSFM) from GIBCO containing 0.09 mM Ca. On day 7, when the cells were 80-90% confluent, they were trypsinized and plated in the serum-free medium for the various experiments.

### **Thymidine Assay**

#### **<sup>3</sup>H-Thymidine Incorporation and Keratinocyte Proliferation**

The incorporation of <sup>3</sup>H-thymidine by cultured keratinocytes was used as an assay of keratinocyte proliferation. Thymidine is one of four deoxynucleosides which are the monomeric units of DNA, the universal library of genetic information in the animal kingdom. Prior to cell division of a somatic cell such as a keratinocyte, the complete genome

of the cell undergoing cell division is replicated. This involves large scale DNA synthesis by the cell and enables both daughter cells to receive identical copies of the genetic material. When  $^3\text{H}$ -thymidine is included in the culture media of keratinocytes which are synthesizing DNA in preparation for cell division then the labelled nucleoside is incorporated into the newly synthesized DNA. The extent of incorporation of  $^3\text{H}$ -thymidine into a population of cells is proportional to the rate of DNA synthesis by this population of cells and therefore an indication of their cellular proliferation.

Keratinocytes (that were cultured as described above) were plated in 24 well plates at a density of 40,000 cells per well in 1 ml media. After incubation for four days or until the cells were 60-70% confluent, the media was changed. Test compounds were added (in triplicate) to the wells 24 hours after the media change, and four hours later  $1\mu\text{Ci } ^3\text{H}$ -Thymidine in 50  $\mu\text{l}$  media was added per well. Cells were incubated for a further 24 hours. Media was removed from the cells, 10% ice cold trichloroacetic acid (TCA) added and plates were incubated on ice for 30 minutes. Cells were washed five times with 5% TCA and allowed to dissolve in 500  $\mu\text{l}$  0.1M NaOH for at least one hour (usually overnight). The preparations were neutralized with 0.1M HCl; 50  $\mu\text{l}$  of the cell preparation was used to determine total protein content. Disintegrations per minute (DPM) from  $^3\text{H}$  labelling of DNA was determined by liquid scintillation counting of 900 $\mu\text{l}$  of the cell preparation. Thymidine incorporation results were expressed as DPM/ $\mu\text{g}$  protein.

### Transglutaminase Assay

#### Transglutaminase Assay and Keratinocyte Differentiation

During the process of terminal differentiation in the epidermis, a 15nm thick layer of protein, known as the cornified envelope (CE) is formed on the inner surface of the cell periphery. The CE is composed of numerous distinct proteins which have been cross-linked together by the formation of N $^{\epsilon}$ -( $\gamma$ -glutamyl) lysine isodipeptide bonds catalyzed by the action of at least two different transglutaminases (TGases) expressed in the epidermis. TGase I is expressed in abundance in the differentiated layers of the epidermis, especially the granular layer, but is absent in the undifferentiated basal epidermis. Thus TGase I is a useful marker of epidermal keratinocyte differentiation with high TGase I levels indicating a more differentiated state. An ELISA based TGase I assay, using a TGase I antibody, was used to assess the state of differentiation of the cultured keratinocytes in the examples that follow.

Keratinocytes (cultured as described above) were plated in 96 well plates at a density of 3,000 cells per well in 200  $\mu\text{l}$  media. After incubation for four days the media was changed to media containing test compounds (six replicates per test). The cells were cultured for a further 72 hours after which time the media was aspirated and the plates stored at  $-70^{\circ}\text{C}$ . Plates were removed from the freezer, and the cells washed with PBS. 100  $\mu\text{l}$  sterile water was added and the cells were freeze fractured by freezing at  $-70^{\circ}\text{C}$  then thawing. The cells were incubated for one hour at room temperature (R/T) with PBS/3% BSA (wash buffer, bovine serum albumin), then rinsed with a fresh aliquot of wash buffer. Cells were incubated with 50  $\mu\text{l}$  of primary antibodies monoclonal anti-human transglutaminase (IgG) obtained from Amersham (mouse) diluted 1:300 in wash buffer for one hour,  $37^{\circ}\text{C}$  then rinsed two times with wash buffer. Cells were then incubated with 50  $\mu\text{l}$  of secondary antibody (Fab fragment, peroxidase conjugated anti-mouse IgG obtained from Amersham) diluted 1:200 in wash buffer for one hour at  $37^{\circ}\text{C}$ , then rinsed two times with wash buffer. Cells were incubated with substrate solution (4 mg o-phenylene diamine and 3.3  $\mu\text{l}$  30%  $\text{H}_2\text{O}_2$  in 10ml 0.1M citrate buffer pH 5.0) for five minutes, R/T, in darkness (under aluminum foil). The reaction was stopped by the addition of 50  $\mu\text{l}$  4N  $\text{H}_2\text{SO}_4$ . The absorbance of samples was read at 492nm in the plate reader. Out of the six replicates, four were treated with both antibodies, two were treated only with the secondary antibody (i.e., to determine background binding of enzyme conjugated Ab). TGase levels were determined by subtracting background from the readings from each treatment and determining mean  $\pm$  s.d. for the replicates exposed to both Ab.

### DNA Assay

The level of TGase-1 detected after treatment of the cells could be influenced by cell number, i.e., the greater the number of cells the greater the level of TGase-1 detected. The level of TGase-1 was normalized to DNA content of the cells in the same well thus eliminating variation due to differences in cell number. DNA quantitation is a particularly useful indicator of cell number, including keratinocyte cell number, because each cell has to all intents and purposes an identical genome and therefore an identical quantity of DNA. The total DNA content of a well of cells therefore is directly proportional to the cell number in that well. Quantitation of DNA was used to normalize the TGase data to cell number.

Keratinocytes were plated in 96 well plates at a density of 3,000 cells per well in 200 $\mu\text{l}$  media. After incubation for four days the media was changed for media containing test compounds (6 replicates per test). The cells were cultured for a further 72 hours after which time the media was aspirated and the plates stored for at least 1.5 hours at  $-70^{\circ}\text{C}$ . Plates were removed from the freezer, and the cells were fixed with cold 1:1 ethanol/acetone solution for 30 minutes. 100 $\mu\text{l}$ /well of Hoechst dye (10 $\mu\text{g}/\text{ml}$  final concentration) was added and this was incubated for 15 minutes, covered

and then read in a fluorimeter (ex. 360nm and em. 460nm). The dye solution was removed and the wells were rinsed with PBS in preparation for the TGase assay.

### EXAMPLE 1

#### Retinoic acid is more effective than retinol at altering keratinocyte differentiation state

A. The effect on incorporation of  $^3\text{H}$ -thymidine/ $\mu\text{g}$  soluble protein 24 hours after the addition of retinoic acid and retinol at various concentrations was examined and the results are shown in Table 1A.

**TABLE 1A**

Treatment	mean Thymidine incorp./ $\mu\text{g}$ protein $\pm$ s.d (% control)	p value vs Control	p value vs $10^{-7}\text{ROH}$	p value vs $10^{-8}\text{ROH}$	p value vs $10^{-9}\text{ROH}$
Control	2094 $\pm$ 140 (100%)	-	0.202	0.501	0.203
$2.5 \times 10^{-7}\text{M}$ RA	2475 $\pm$ 116 (118%)	0.005	0.032	0.004	0.002
$2.5 \times 10^{-7}\text{M}$ ROH	2218 $\pm$ 73 (106%)	0.202	-	0.021	0.005
$2.5 \times 10^{-8}\text{M}$ RA	2686 $\pm$ 72 (128%)	0.001	0.001	0.001	0.001
$2.5 \times 10^{-8}\text{M}$ ROH	2034 $\pm$ 46 (97%)	0.501	0.021	-	0.121
$2.5 \times 10^{-9}\text{M}$ RA	2556 $\pm$ 80 (122%)	0.001	0.006	0.001	0.001
$2.5 \times 10^{-9}\text{M}$ ROH	1977 $\pm$ 19 (94%)	0.203	0.005	0.121	-

n = 3

All concentrations of retinoic acid tested, i.e.,  $2.5 \times 10^{-7}\text{M}$ ,  $2.5 \times 10^{-8}\text{M}$  and  $2.5 \times 10^{-9}\text{M}$ , significantly increased keratinocyte proliferation over both the ethanol control and each of the  $2.5 \times 10^{-7}\text{M}$ ,  $2.5 \times 10^{-8}\text{M}$  and  $2.5 \times 10^{-9}\text{M}$  retinol treatments and they did so in a dose dependant manner. This is consistent with retinoic acid having a greater stimulatory effect on epithelial proliferation than retinol.

B. The effect on Transglutaminase levels normalized to DNA content of the cells after addition of retinoic acid and retinol was examined and the results are shown in Table 1B.

**TABLE 1B**

Treatment	mean TGase/ DNA $\times 10^4 \pm$ s.d (% control)	p value vs Control	p value vs $10^{-7}$ ROH	p value vs $10^{-8}$ ROH	p value vs $10^{-9}$ ROH
Control	$2.44 \pm 0.24$ (100%)	-	0.001	0.001	0.001
$2.5 \times 10^{-7}$ M RA	$0.16 \pm 0.11$ (7%)	0.001	0.001	0.001	0.001
$2.5 \times 10^{-7}$ M ROH	$1.14 \pm 0.22$ (47%)	0.001	-	0.001	0.001
$2.5 \times 10^{-8}$ M RA	$1.34 \pm 0.40$ (55%)	0.001	0.001	0.001	0.001
$2.5 \times 10^{-8}$ M ROH	$1.89 \pm 0.30$ (77%)	0.001	0.001	-	0.001
$2.5 \times 10^{-9}$ M RA	$1.87 \pm 0.49$ (77%)	0.001	0.001	0.784	0.001
$2.5 \times 10^{-9}$ M ROH	$2.70 \pm 0.59$ (>100%)	0.001	0.001	0.001	-

n = 3

All concentrations of retinoic acid tested, i.e.,  $2.5 \times 10^{-7}$ M,  $2.5 \times 10^{-8}$ M and  $2.5 \times 10^{-9}$ M decreased keratinocyte TGase level over both the ethanol control and did so to a significantly greater extent than each of the corresponding  $2.5 \times 10^{-7}$ M,  $2.5 \times 10^{-8}$ M and  $2.5 \times 10^{-9}$ M retinol treatments. The decrease in transglutaminase level was dose dependant for both retinoic acid and retinol. This is consistent with retinoic acid having a greater inhibitory effect on epithelial differentiation than retinol.

**EXAMPLE 2****Dimethyl Imidazolidinone and Retinol Synergistically****Enhanced Keratinocyte Proliferation**

A. The effect on incorporation of  $^3\text{H}$ -thymidine/ $\mu\text{g}$  soluble protein 24 hours after addition of the test compounds was examined and the results are shown in Table 2A.

**TABLE 2**

Treatment	mean Thymidine incorp/μg protein ± s.d (% control)	p value vs Control	p value vs 10 <sup>-9</sup> ROH	p value vs 10 <sup>-9</sup> RA	p valu vs 10 <sup>-9</sup> lino- DEA
Control	2094 ± 140 (100%)	-	-	-	-
2.5x10 <sup>-8</sup> M RA	2686 ± 72 (128%)	0.000	0.000	-	-
2.5x10 <sup>-8</sup> M Retinol	2034 ± 46 (97%)	0.501	-	0.000	-
10 <sup>-9</sup> M Dimethyl imidazolidinone	2003 ± 128 (96%)	0.373	-	-	-
2.5x10 <sup>-8</sup> M ROH + 10 <sup>-9</sup> M Dimethyl imidazolidinone	2518 ± 102 (120%)	0.002	0.002	0.001	0.025

n = 3

2.5 x 10<sup>-8</sup>M retinoic acid significantly increased keratinocyte thymidine incorporation over both the ethanol control and the 2.5 x 10<sup>-8</sup>M retinol treatment by 28%. 10<sup>-9</sup>M dimethyl imidazolidinone had no effect on keratinocyte proliferation on its own. However, the combination of 2.5 x 10<sup>-8</sup>M retinol + 10<sup>-9</sup>M dimethyl imidazolidinone significantly increased keratinocyte proliferation over both the ethanol (by 20%) and the 2.5 x 10<sup>-8</sup>M retinol control treatments (by 23%). Dimethyl imidazolidinone and retinol therefore, act synergistically to increase keratinocyte proliferation to levels which closely resemble the stimulatory effect of retinoic acid.

**EXAMPLE 3****The Synergistic Increase in Keratinocyte Proliferation Induced****By Retinol and Dimethyl Imidazolidinone is Most Effective at ROH:Dimethyl Imidazolidinone Ratios Ranging From 60:1 to 1:160**

In order to determine the range of retinol:dimethyl imidazolidinone ratios which were most effective at enhancing the benefit of retinol, the effect on incorporation of <sup>3</sup>H-thymidine/μg soluble protein 24 hours after the addition of retinol and linoleamide-DEA in different ratios of amounts, was examined. These were compared to the effects of retinoic acid at equimolar concentrations (with respect to retinol) and the effects of retinol and dimethyl imidazolidinone alone and the results are presented in Table 3A.

Retinoic acid treatment acted as positive control and all concentrations of retinoic acid tested, i.e., 2.5 x 10<sup>-7</sup> M, 2.5 x 10<sup>-8</sup>M and 2.5 x 10<sup>-9</sup>M, significantly increased keratinocyte proliferation over both the ethanol control and each of the 2.5 x 10<sup>-7</sup>M, 2.5 x 10<sup>-8</sup>M and 2.5 x 10<sup>-9</sup>M retinol treatments. Five combinations of retinol and linoleamide were examined with retinol concentrations of 2.5 x 10<sup>-7</sup>M, 2.5 x 10<sup>-8</sup>M and 2.5 x 10<sup>-9</sup>M and dimethyl imidazolidinone concentrations of 10<sup>-6</sup>M - 10<sup>-9</sup>M. The ratios of retinol:dimethyl imidazolidinone therefore ranged from 60:1 to 1:160 as is illustrated in Table 3B. The synergistic increase indicated in Table 3B is equal to the % control thymidine incorporation of the ROH + dimethyl imidazolidinone treatment which exceeds the combined individual ROH and dimethyl imidazolidinone treatment. All five combinations showed a synergistic increase in thymidine incorporation/soluble protein. The increased cell proliferation was statistically significant. The trend is clear - combinations of retinol and dimethyl imidazolidinone at ratios ranging from at least 60:1 through 1:160 synergistically increase keratinocyte cell proliferation.



**TABLE 3A**

Treatment	mean Thymidine Incorp/ $\mu$ g protein $\pm$ s.d (% control)	p value vs Control	p value vs $10^{-6}$ ROH	p value vs $10^{-6}$ RA	p value vs $10^{-6}$ Imidaz
Control	2094 $\pm$ 140 (100%)	-	-	-	-
$2.5 \times 10^{-7}$ M RA	2475 $\pm$ 116 (118%)	0.006	0.032	-	-
$2.5 \times 10^{-6}$ M RA	2686 $\pm$ 72 (128%)	0.000	0.000	-	-
$2.5 \times 10^{-6}$ M RA	2556 $\pm$ 80 (122%)	0.001	0.000	-	-
$2.5 \times 10^{-7}$ M Retinol	2218 $\pm$ 79 (106%)	0.202	-	0.032	-
$2.5 \times 10^{-6}$ M Retinol	2034 $\pm$ 46 (97%)	0.501	-	0.000	-
$2.5 \times 10^{-6}$ M Retinol	1977 $\pm$ 19 (94%)	0.203	-	0.000	-
$10^{-6}$ M Dimethyl imidazolidinone	1892 $\pm$ 119 (90%)	0.07	-	-	-
$10^{-7}$ M Dimethyl imidazolidinone	2260 $\pm$ 166 (108%)	0.157	-	-	-
$10^{-6}$ M Dimethyl imidazolidinone	2003 $\pm$ 128 (96%)	0.375	-	-	-
$2.5 \times 10^{-7}$ M ROH + $10^{-6}$ M Dimethyl imidazolidinone	2426 $\pm$ 76 (116%)	0.007	0.027	0.560	0.003
$2.5 \times 10^{-6}$ M ROH + $10^{-6}$ M Dimethyl imidazolidinone	2565 $\pm$ 26 (122%)	0.001	0.000	0.052	0.001
$2.5 \times 10^{-6}$ M ROH + $10^{-6}$ M Dimethyl imidazolidinone	2518 $\pm$ 102 (120%)	0.002	0.002	0.081	0.025
$2.5 \times 10^{-6}$ M ROH + $10^{-6}$ M Dimethyl imidazolidinone	2397 $\pm$ 96 (114%)	0.013	0.002	0.001	0.005
$2.5 \times 10^{-6}$ M ROH + $10^{-7}$ M Dimethyl imidazolidinone	2667 $\pm$ 172 (127%)	0.001	0.002	0.360	0.042
$2.5 \times 10^{-6}$ M ROH + $10^{-6}$ M Dimethyl imidazolidinone	2379 $\pm$ 97 (114%)	0.017	0.002	0.072	0.055

n = 3

**TABLE 3B**

Ratio (ROH:DMI)	Treatment	<u>Thymidine</u> <u>Incorp<sup>n</sup></u>			Synergistic Increase
		Control	ROH	DMI	
60:1	$2.5 \times 10^{-4} \text{M}$ ROH + $10^{-9} \text{M}$ Dimethyl imidazolidinone	100% *	97% *	96% *	120% * (20%)
6:1	$2.5 \times 10^{-4} \text{M}$ ROH + $10^{-4} \text{M}$ Dimethyl imidazolidinone	100% *	94% *	96% *	114% * (14%)
1:2	$2.5 \times 10^{-7} \text{M}$ ROH + $10^{-4} \text{M}$ Dimethyl imidazolidinone	100% *	106% *	90% *	116% * (10%)
1:16	$2.5 \times 10^{-4} \text{M}$ ROH + $10^{-4} \text{M}$ Dimethyl imidazolidinone	100% *	97% *	90% *	122% * (22%)
1:16	$2.5 \times 10^{-4} \text{M}$ ROH + $10^{-7} \text{M}$ Dimethyl imidazolidinone	100% *	94% *	108% *	127% * (19%)
1:160	$2.5 \times 10^{-4} \text{M}$ ROH + $10^{-6} \text{M}$ Dimethyl imidazolidinone	100% *	94% *	90% *	114% * (14%)

n = 3

\* = p &lt; 0.05

**EXAMPLE 4****Dimethyl Imidazolidinone and Retinyl Palmitate****Synergistically Enhanced Keratinocyte Proliferation**

A. The effect on incorporation of  $^3\text{H}$ -thymidine/ $\mu\text{g}$  soluble protein 24 hours after addition of the test compounds was examined and the results are shown in Table 4A.

**TABLE 4A**

**Effect of Retinyl Palmitate and Dimethyl Imidazolidinone**  
**on Keratinocyte Thymidine Incorporation**

Treatment	mean Thymidine incorp/μg protein ± s.d (% control)	p value vs Contr 1	p value vs $10^{-8}$ RP	p value vs $10^{-8}$ RA	p value vs $10^{-7}$ DMI
Control	3477 ± 258 (100%)	-	-	-	-
$2.5 \times 10^{-8}$ M RA	3691 ± 205 (106%)	0.098	0.082	-	-
$2.5 \times 10^{-8}$ M Retinyl Palmitate (RP)	3386 ± 326 (97%)	0.528	-	0.082	-
$10^{-7}$ M Dimethyl imidazolidinone (DMI)	3214 ± 128 (92%)	0.112	-	-	-
$2.5 \times 10^{-8}$ M RP + $10^{-7}$ M Dimethyl imidazolidinone	3812 ± 95 (110%)	0.050	0.069	0.377	0.001

n = 3

$2.5 \times 10^{-8}$  M retinoic acid increased keratinocyte thymidine incorporation over both the ethanol control and the  $2.5 \times 10^{-8}$  M retinyl palmitate treatment by 6%.  $10^{-7}$  M dimethyl imidazolidinone had no effect on keratinocyte proliferation on its own. However the combination of  $2.5 \times 10^{-8}$  M retinyl palmitate +  $10^{-7}$  M dimethyl imidazolidinone significantly increased keratinocyte proliferation over both the ethanol (by 10%) and the  $2.5 \times 10^{-8}$  M retinyl palmitate control treatments (by 13%). Dimethyl imidazolidinone and retinyl palmitate therefore, act synergistically to increase keratinocyte proliferation.

B. The effect on TG1 in response to treatment with retinyl palmitate and dimethyl imidazolidinone was examined and the results are shown in Table 4B.

**TABLE 4B**

**Effect of Retinyl Palmitate and Dimethyl Imidazolidinone on Keratinocyte TGase Levels**

Treatment	mean TGase ± s.d (% control)	p value vs Control	p value vs $10^{-8}$ RP	p value vs $10^{-8}$ DMI
Control	1.00 ± 0.289 (100%)	-	0.130	0.268
$2.5 \times 10^{-8}$ M RA	0.155 ± 0.098 (16%)	0.001	0.001	0.001
$2.5 \times 10^{-8}$ M Retinyl palmitate (RP)	0.790 ± 0.387 (79%)	0.001	-	0.001
$10^{-8}$ M dimethyl imidazolidinone (DMI)	0.990 ± 0.251 (99%)	0.759	0.001	-
$2.5 \times 10^{-8}$ M RP + $10^{-8}$ M dimethyl imidazolidinone	0.574 ± 0.284 (57%)	0.001	0.001	0.001

n = 3

$2.5 \times 10^{-8}$  M retinoic acid was the most effective treatment at repressing keratinocyte TG1 levels (to 15% of control level).  $2.5 \times 10^{-8}$  M retinyl palmitate also repressed TG1 levels to 79% of control levels but not as effective as retinoic acid.  $10^{-8}$  M dimethyl imidazolidinone on its own had no effect on keratinocyte TG1 levels. However,  $2.5 \times 10^{-8}$  M retinyl palmitate +  $10^{-8}$  M dimethyl imidazolidinone repressed keratinocyte TG1 levels to 57% of control level. Dimethyl imi-

dazolidinone and retinyl palmitate therefore, act synergistically to repress keratinocyte differentiation to in a manner analogous to the effect of retinoic acid.

In Examples 1-4, retinoic acid was used as positive control and reference compound against which the other compounds under analysis were compared. Retinoic acid, in a dose dependant manner, increased thymidine incorporation and decreased transglutaminase I levels in skin keratinocytes. In other words, retinoic acid increased keratinocyte proliferation and decreased keratinocyte differentiation. Retinol or retinyl palmitate was significantly less effective than retinoic acid at inhibiting keratinocyte differentiation and completely ineffective at increasing keratinocyte proliferation.

The effect of retinol or retinyl palmitate on cultured keratinocytes can be enhanced to levels approaching those of retinoic acid by combining retinol or retinyl palmitate with dimethyl imidazolidinone which exerts little or no benefit on their own.

Dimethyl imidazolidinone acts synergistically with retinol or retinyl palmitate both to increase keratinocyte proliferation and decrease keratinocyte differentiation, mimicking the effect of retinoic acid.

#### EXAMPLE 5

This example illustrates a high internal phase water-in-oil emulsion incorporating the inventive composition.

	% w/w
Retinol	0.5
Fully hydrogenated coconut oil	3.9
1,3-dimethyl-2-imidazolidinone	0.2
Brij 92*	5
Bentone 38	0.5
MgSO <sub>4</sub> ·7H <sub>2</sub> O	0.3
Butylated hydroxy toluene	0.01
Perfume	qs
Water	to 100

\* Brij 92 is polyoxyethylene (2) oleyl ether

#### EXAMPLE 6

This example illustrates an oil-in-water cream incorporating the inventive composition.

5

10

15

20

25

	% w/w
Retinol	0.15
Mineral oil	4
1,3-dimethyl-2-imidazolidinone	1
Brij 56*	4
Alfol 16RD*	4
Triethanolamine	0.75
Butane-1,3-diol	3
Xanthan gum	0.3
Perfume	qs
Butylated hydroxy toluene	0.01
Water	to 100

\* Brij 56 is cetyl alcohol POE (10)  
Alfol 16RD is cetyl alcohol

30

**EXAMPLE 7**

This example illustrates an alcoholic lotion incorporating the composition according to the invention.

35

40

45

	% w/w
Retinyl palmitate	0.15
1,3-dimethyl-2-imidazolidinone	0.1
Ethanol	40
Perfume	qs
Butylated hydroxy toluene	0.01
Water	to 100

50

**EXAMPLE 8**

This example illustrates another alcoholic lotion containing the inventive composition.

55

5

10

15

	% w/w
Retinol	0.15
1,3-dimethyl-2-imidazolidinone	0.01
Ethanol	40
Antioxidant	0.1
Perfume	qs
Water	to 100

**EXAMPLE 9**

20

This example illustrates a suncare cream incorporating the composition of the invention:

25

30

35

40

45

	% w/w
Retinol	0.01
1,3-dimethyl-2-imidazolidinone	0.2
Silicone oil 200 cts	7.5
Glycerylmonostearate	3
Cetosteryl alcohol	1.6
Polyoxyethylene-(20)-cetyl alcohol	1.4
Xanthan gum	0.5
Parsol 1789	1.5
Octyl methoxycinnate (PARSOL MCX)	7
Perfume	qs
Color	qs
Water	to 100

**EXAMPLE 10**

50

This example illustrates a non-aqueous skin care composition incorporating the inventive combination.

55

		% w/w
5	Retinyl palmitate	0.15
	1,3-dimethyl-2-imidazolidinone	1
	Silicone gum SE-30 <sup>1</sup>	10
10	Silicone fluid 345 <sup>2</sup>	20
	Silicone fluid 344 <sup>3</sup>	55.79
15	Squalene	10
	Linoleic acid	0.01
	Cholesterol	0.03
20	2-hydroxy-n-octanoic acid	0.7
	Vitamin E linoleate	0.5
	Herbal oil	0.5
25	Ethanol	2

<sup>1</sup> A dimethyl silicone polymer having a molecular weight of at least 50,000 and a viscosity of at least 10,000 centistokes at 25°C, available from GEC

<sup>2</sup> Dimethyl siloxane cyclic pentamer, available from Dow Corning Corp.

<sup>3</sup> Dimethyl siloxane tetramer, available from Dow Corning Corp.

#### Claims

1. A skin conditioning composition comprising:

(a) from 0.001% to 10% of a compound selected from the group consisting of retinol and a retinyl ester;

(b) from 0.001% to 10% of dimethyl imidazolidinone; and

(c) a cosmetically acceptable vehicle.

2. The composition of claim 1 wherein the retinyl ester is selected from the group consisting of retinyl palmitate, retinyl acetate, retinyl propionate, and mixtures thereof.

3. The composition of claim 1 wherein the ratio of ingredient (a) to ingredient (b) is in the range of from 60:1 to 1:160.

4. The use of a composition according to claim 1 in the manufacture of an agent for conditioning of skin.

5. The use of a composition according to claim 1 in the manufacture of an agent for mimicking the effect on skin of retinoic acid.



European Patent  
Office

# EUROPEAN SEARCH REPORT

Application Number  
EP 96 30 3183

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	EP-A-0 586 106 (JOHNSON & JOHNSON ) 9 March 1994 * claim 1 *	1	A61K7/48
A	EP-A-0 609 963 (JANSSEN PHARMACEUTICA) * claims 1,8 *	1,4	
A	EP-A-0 508 848 (L'OREAL ) 14 October 1992 * claim 1 *	1	
A	FR-A-2 558 058 (P. F. MEDICAMENT) 19 July 1985 * claim 1 *	1	
A	GB-A-2 097 783 (DERMAL LABORATORIES) 10 November 1982 * claim 1 *	1	
D,A	WO-A-93 19743 (THE REGENTS OF THE UNIVERSITY OF MICHIGAN) 14 October 1993 * claim 1 *	4	
The present search report has been drawn up for all claims			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			A61K
Place of search		Date of completion of the search	Examiner
THE HAGUE		11 October 1996	Voyiazoglou, D
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons &amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 01/92 (P04C01)